Ignite Creation Date:
2025-12-24 @ 11:07 PM
Ignite Modification Date:
2025-12-28 @ 8:44 AM
Study NCT ID:
NCT00001669
Status:
COMPLETED
Last Update Posted:
2008-03-04
First Post:
1999-11-03
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients
Sponsor:
National Institute of Neurological Disorders and Stroke (NINDS)
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
1997-07
Start Date Type:
None
Primary Completion Date:
None
Primary Completion Date Type:
None
Completion Date:
2000-04
Completion Date Type:
None
First Submit Date:
1999-11-03
First Submit QC Date:
None
Study First Post Date:
2002-12-10
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2008-03-03
Last Update Post Date:
2008-03-04
Last Update Post Date Type:
ESTIMATED